BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, has experienced growing demand for its robust educational offerings, leading to an increase in the number of dental laser courses planned for the first quarter of 2024. The full list of both in-person and virtual course options can be found on BIOLASE’s education web portal at Education.Biolase.com, which offers tailored education pathways through the Waterlase Academy and Epic Diode Academy.
The Waterlase Academy provides resources and educational content for the Company’s Waterlase all-tissue laser, while the Epic Diode Academy serves as the educational hub for the Company’s Epic diode laser product.
The Waterlase Academy is offering a broad range of classroom courses, starting with the Advanced Mastery Course on February 2–3, 2024, at the BIOLASE Education Center, the Company’s new, state-of-the-art training facility in Foothill Ranch, CA. The BIOLASE Education Center has access to a surgical dental suite for live patient education, providing dental clinicians with a comfortable, engaging learning environment tailored to laser education. Following the Advanced Mastery Course are several Foundation Courses, forming the core curriculum for all new Waterlase owners. BIOLASE also offers specialized courses in endodontics, periodontics, and pediatric dentistry to provide quality education in various areas of dentistry.
To extend education into facial aesthetics, BIOLASE will host a seminar on February 16, 2024, focusing on all-tissue laser therapies designed for esthetic procedures and extra-oral skin resurfacing using the Company’s new fractional handpiece. The seminar will also take place at the BIOLASE Education Center.
To ensure dental clinicians stay at the forefront of hygiene laser education, the Epic Diode Academy offers monthly virtual hygiene diode courses covering pocket therapy, periodontal debridement, management of oral ulcerations, and hemostasis. Additionally, the Epic Diode Academy provides multiple virtual surgical diode courses focused on the clinical utilization of diode lasers, with instruction in an innovative virtual hands-on environment.
BIOLASE plans to continue expanding its educational offerings through Education.Biolase.com, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. As of December 31, 2022, BIOLASE’s proprietary laser products incorporate approximately 259 patented and 24 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2022, BIOLASE has sold over 45,500 laser systems in over 80 countries worldwide. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus, Waterlase Express, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE, Waterlase, and Waterlase iPlus are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as defined in the Private Litigation Reform Act of 1995, involving significant risks and uncertainties, including statements regarding BIOLASE’s expected revenue and revenue growth, and beliefs regarding its financial resources. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release.
Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties described in the “Risk Factors” section of BIOLASE’s most recent annual report filed on Form 10-K with the Securities and Exchange Commission (SEC), and risk factors described in subsequent filings with the SEC. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
